For many years, lots of India pharma companies have been actively exploring global markets because they felt this was where the growth and the profits were. However, they've burned their fingers for two major reasons. Firstly, the negative US FDA inspection reports of their plants has damaged their reputation. This has hurt their image as well as their bottom line , and this has caused their share prices to take a beating. Equally importantly, markets in USA and Europe have become extremely competitive . The early movers made a lot of money by exploring the generic market, and they could take advantage of the pricing difference.